Diaceutics
DXRX · AIM · Health Care · mcap £166m · 203.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 07 Oct 26 | Holding | Holding(s) in Company | |
| 07 Oct 26 | Routine | Block Listing Return | |
| 06 Oct 26 | Director dealing | PDMR Shareholding/SIP and Total Voting Rights | |
| 24 Sep 26 | Diaceutics and Syndax expand Relay partnership
Expanded partnership to support the commercialization of a diagnostic-driven therapy and help identify and treat eligible patients sooner |
+0.8% | |
| 22 Sep 26 | Results | Half-year Results
Interim Results for the six months ended 30 June 2026 |
+9.4% |
| 08 Sep 26 | Routine | Notice of Results & Presentations | |
| 02 Sep 26 | Director dealing | PDMR Shareholding/SIP & Total Voting Rights | |
| 20 Aug 26 | Diaceutics and PCC launch NGS Concordance Study
Diaceutics and PCC launch NGS Concordance Study to advance precision oncology and support informed biomarker testing |
−4.2% | |
| 04 Aug 26 | Director dealing | PDMR Shareholding/Share Incentive Plan & TVRs | |
| 29 Jul 26 | 75% ARR Growth Drives Revenue & Profit Visibility
Strong ARR growth of 75% drives H2 2026 revenue and profit visibility |
+4.3% | |
| 03 Jul 26 | Director dealing | PDMR Shareholding/Share Incentive Plan and TVRs | |
| 25 Jun 26 | Routine | Result of AGM | |
| 01 Jun 26 | Director dealing | PDMR Shareholding/Share Incentive Plan & TVRs | |
| 29 May 26 | Routine | Notice of AGM & Posting of Annual Report | |
| 26 May 26 | Results | Final Results
Revenue growth of 24% on a constant currency basis to £38.4 million in FY 2025 |
−9.3% |
| 13 May 26 | Routine | Notice of Results | |
| 12 May 26 | Holding | Holding(s) in Company | |
| 05 May 26 | Director dealing | PDMR Shareholding/Share Incentive Plan and TVRs | |
| 16 Apr 26 | Related Party Transaction - Lease Extension
New York, Belfast and London, 16 April 2026 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announces that it has agreed an extension to its existing property |
+0.0% | |
| 07 Apr 26 | Routine | Block Listing Return | |
| 01 Apr 26 | Director dealing | PDMR Shareholding/SIP & Total Voting Rights | |
| 03 Mar 26 | Director dealing | PDMR Shareholding/Share Incentive Plan and TVRs | |
| 03 Feb 26 | Director dealing | PDMR Shareholding/Share Incentive Plan & TVR | |
| 15 Jan 26 | Trading update | Full Year 2025 Trading Update
Reported revenues expected to be £38.5 million, representing 20% growth and a return to profitability |
+10.2% |
| 23 Dec 25 | Director dealing | PDMR Shareholding/SIP & Total Voting Rights | |
| 28 Nov 25 | Director dealing | PDMR Shareholding/SIP & Total Voting Rights | |
| 04 Nov 25 | Director dealing | PDMR Shareholding/Share Incentive Plan and TVR | |
| 07 Oct 25 | Routine | Block listing Interim Review |
Company filings. Not investment advice.